Strides Arcolab receive US FDA approval for lamivudine & zidovudine tablets
Strides Arcolab Limited has got approval from the United States Food & Drug Administration (FDA) for lamivudine and zidovudine tablets USP, 150 mg/300 mg for HIV therapy.
[adsense:336x280:8701650588]
The product will be manufactured at the company’s oral dosage facility at Bengaluru. The product will be launched in the US markets immediately
[adsense:468x15:2204050025]
Lamivudine and zidovudine 150 mg/300 mg (generic version of Viiv's Combivir) belong to a class of antiviral medicines and is used with other antiretroviral medicines to treat HIV infection in adults and children. Lamivudine and zidovudine 150 mg/300 mg tablets reduces the amount of HIV in your body, and keeps it at a low level.
Subscribe to PharmaTutor News Alerts by Email >>